XML 21 R46.htm IDEA: XBRL DOCUMENT v3.2.0.727
ACQUISITIONS AND DIVESTITURES (Acquisition of Coodetec) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2015
Jun. 30, 2015
Jan. 30, 2015
Dec. 31, 2014
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net   $ 3,892   $ 3,735
Indefinite-Lived Intangible Assets (Excluding Goodwill) [1]   79   33
Trademarks [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net   265   276
Customer related [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net   1,959   2,077
Other Intangible Assets [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net   $ 28   $ 12
Coodetec [Member]        
Business Acquisition [Line Items]        
Purchase Price $ 169      
Payments to Acquire Businesses, Gross 79      
Noncash or Part Noncash Acquisition, Payables Assumed $ 16      
Inventories     $ 24  
Property     35  
Other intangible assets [2]     81  
Total Assets Acquired     140  
Accrued and other current liabilities     2  
Total Liabilities Assumed     2  
Goodwill     31  
Indefinite-Lived Intangible Assets (Excluding Goodwill) [1]     46  
Coodetec [Member] | In Process Research and Development [Member]        
Business Acquisition [Line Items]        
Indefinite-Lived Intangible Assets (Excluding Goodwill)     46  
Coodetec [Member] | Trademarks [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net     14  
Coodetec [Member] | Customer related [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net     1  
Coodetec [Member] | Other Intangible Assets [Member]        
Business Acquisition [Line Items]        
Finite-Lived Intangible Assets, Net     $ 20  
[1] In-process research and development (“IPR&D”) purchased in a business combination.
[2] Includes $14 million of trademarks, $1 million of customer-related intangibles, $20 million of germplasm and $46 million of in-process research and development. See Note 6 for additional information.